M. E. Scheulen

Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid Tumors

Dirk Strumberg, Heike Richly, Ralf A. Hilger et al. · Journal of Clinical Oncology · 2004 · 871 citations · Full text

Medicine, Oncology, Pharmacology +16

Phase II Study of Temsirolimus (CCI-779), a Novel Inhibitor of mTOR, in Heavily Pretreated Patients With Locally Advanced or Metastatic Breast Cancer

Stephen Chan, M. E. Scheulen, S. Johnston et al. · Journal of Clinical Oncology · 2005 · 468 citations · Full text

Medicine, Oncology, Pharmacology +16

A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas

Jeffrey R. Infante, Bradley G. Somer, Joon Oh Park et al. · European Journal of Cancer · 2014 · 363 citations

Medicine, Oncology, Pharmacology +15

Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study

Dirk Strumberg, M. E. Scheulen, Beate Schultheis et al. · British Journal of Cancer · 2012 · 254 citations · Full text

Medicine, Oncology, Pharmacology +16

Pharmacokinetics of a novel anticancer ruthenium complex (KP1019, FFC14A) in a phase I dose-escalation study

Frederike Lentz, Anne Drescher, Andreas Lindauer et al. · Anti-Cancer Drugs · 2009 · 237 citations

Medicine, Pharmacokinetics, Pharmacology +10